Our data suggest the application of anti-iNKT TCR mAbs in the clinic to treat CD32+ tumors, such as leukemia and lymphoma, by inducing reverse ADCC, although humanization of anti-iNKT TCR mAbs might be needed. The gene discussed is FCGR2A; the disease is lymphoma.